Literature DB >> 30227505

The Effectiveness of the Summary of Product Characteristics (SmPC) and Recommendations for Improvement.

David K Raynor1, Peter De Veene2, David Bryant3.   

Abstract

One of the roles of the Summary of Product Characteristics (SmPC) is to provide information for health professionals. The objective of this work was to understand the effectiveness of the SmPC document in communicating essential information to prescribers. The process of user testing, widely used to test information for patients, was applied. First, 30 general practitioners were involved in the testing of the SmPC for Lariam, an antimalarial drug. As user testing is an iterative process, 15 points of information in the original SmPC were tested in 3 rounds of 10 participants. The document was revised between rounds according to the results; good practice in information writing and design was used. Next, the SmPC for CellCept, an immunosuppressant, was tested in 20 senior hospital doctors. Again, the document was revised between rounds, according to the results, with revisions also taking account of findings from the Lariam testing related to the general structure of SmPCs. Of the 15 points of information tested, for the original Lariam SmPC, 6 points of information met the target of 90% to find, and 90% of those to understand, whereas for the final version of the CellCept SmPC, 11 points of information met this target. Qualitative comments showed that in their current format, SmPCs are of low perceived value to prescribers and are not central to the clinicians' prescribing behavior. Current content and presentation of SmPCs, while meeting regulatory approval standards, contribute little to the safe and effective use of medication in practice. Key recommendations include revising and simplifying the heading structure and making the headings more visible, adding a "Key Information" summary at the start, using simpler language, and adding bullet points for listings.

Entities:  

Keywords:  Summary of Product Characteristics (SmPC); drug information; readability; user testing

Year:  2014        PMID: 30227505     DOI: 10.1177/2168479013501311

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  5 in total

1.  User-testing guidelines to improve the safety of intravenous medicines administration: a randomised in situ simulation study.

Authors:  Matthew D Jones; Anita McGrogan; D K Raynor; Margaret C Watson; Bryony Dean Franklin
Journal:  BMJ Qual Saf       Date:  2020-06-30       Impact factor: 7.035

Review 2.  The Quality and Reliability of Information in the Summaries of Product Characteristics.

Authors:  Ewelina Drelich; Urszula Religioni; Kevin Chung; Justyna Kaźmierczak; Eliza Blicharska; Agnieszka Neumann-Podczaska; Jerzy Krysiński; Piotr Merks
Journal:  Int J Environ Res Public Health       Date:  2022-02-15       Impact factor: 3.390

3.  Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs.

Authors:  Susanne Haag; Lisa Junge; Fabian Lotz; Natalie McGauran; Marios Paulides; Regine Potthast; Thomas Kaiser
Journal:  J Patient Rep Outcomes       Date:  2021-12-07

4.  Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications-A Systematic Analysis of SmPCs/PI of Major Drug Markets.

Authors:  Laura Weisbach; Anna K Schuster; Michael Hartmann; Martin F Fromm; Renke Maas; Katrin Farker
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

5.  User Testing to Improve Retrieval and Comprehension of Information in Guidelines to Improve Medicines Safety.

Authors:  Matthew D Jones; Bryony Dean Franklin; Margaret C Watson; D K Raynor
Journal:  J Patient Saf       Date:  2022-01-01       Impact factor: 2.844

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.